Retinitis Pigmentosa Clinical Trials
Here are the 6 most popular medical studies for retinitis pigmentosa
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
This trial is testing if N-acetylcysteine, an antioxidant, can help treat Retinitis Pigmentosa, a disease which causes progressive vision loss and eventual blindness. So far, the maximum tolerated dose of NAC has been 1800mg twice a day.
Gene Therapy
Gene Therapy with Light-Stimulating Glasses for Retinitis Pigmentosa
This trial is testing a gene therapy called GS030-DP for safety and tolerability in people with a disease called Retinitis Pigmentosa. The therapy is given as a single injection and then the person wears special glasses that provide light stimulation.
Gene Therapy
RST-001 for Retinitis Pigmentosa
This trial is testing an experimental treatment for macular degeneration. It is enrolling 12 patients total, 6 of which must have very poor vision in the study eye, and 6 of which must have vision ranging from poor to 20/200.
Cell Therapy
hRPC for Retinitis Pigmentosa
This trial is testing a cell therapy for retinitis pigmentosa, in which participants will receive a single injection of hRPC cells in one eye. The goal is to evaluate safety and tolerability, with some preliminary testing of efficacy.
Popular filter options for retinitis pigmentosa trials
RP Clinical Trials
View 30 RP medical studies.
Stem Cell Therapy
Stem Cell Implantation for Retinitis Pigmentosa
This trial is examining the safety of transplanting a type of stem cell, called neural progenitor cells, into the subretinal space of patients with Retinitis Pigmentosa. These cells have been derived to become astrocytes, which are a type of neuronal cell. The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, the investigators want to learn if these cells are safe to transplant into the subretinal space of people.
Retinitis Pigmentosa Clinical Trials With No Placebo
View 30 retinitis pigmentosa medical studies that do not have a placebo group.
Stem Cell Therapy
Stem Cell Implantation for Retinitis Pigmentosa
This trial is examining the safety of transplanting a type of stem cell, called neural progenitor cells, into the subretinal space of patients with Retinitis Pigmentosa. These cells have been derived to become astrocytes, which are a type of neuronal cell. The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, the investigators want to learn if these cells are safe to transplant into the subretinal space of people.
View More Retinitis Pigmentosa Trials
See another 5 medical studies focused on retinitis pigmentosa.
Frequently Asked Questions
Introduction to retinitis pigmentosa
What are the top hospitals conducting retinitis pigmentosa research?
When it comes to advancing the understanding and treatment of retinitis pigmentosa, several leading hospitals are making significant strides. In Dallas, the Retina Foundation of the Southwest is at the forefront with five ongoing clinical trials dedicated to this rare eye disorder. With a remarkable total of 20 completed trials since initiating their first study in 2004, this institution has been pivotal in shedding light on retinitis pigmentosa. Meanwhile, in Pittsburgh, the UPMC Eye Center is actively conducting three trials for this condition. Although relatively new in terms of its research endeavors, having started their first trial in 2017, they have already made valuable contributions towards unraveling the mysteries surrounding retinitis pigmentosa.
In Gainesville's Vitreo Retinal Associates center researchers too are focusing much on finding potential treatments for patients suffering from vision loss caused by retinitis pigmentosa where they run three active clinical examinations while keeping track of previously four held medical studies starting from only last year around2020.Universityof Michigan stands out as another formidable player by offering similar approach with holding three ongoing tests among which being no less than pioneers;it was back thereyears ago that itsfirst initiative began specifically addressingretinitispigmentosawhile DukeEyeCenter exhibits equally promising dedication by running additionalthreeactive investigations following footsteps throughfive previous experiments since stepping intothisjourney aimedat tacklingthe diseasefour years earlierin2015.
These esteemed institutions serve as beacons of hope for those affected by retinitis pigmentosa—a progressive and inherited degenerative eye disorder that often leads to severe visual impairment or blindness. Their collective efforts not only pave the way for potential breakthroughs but also underline the commitment and determination within the medical community to provide better care and quality of life for individuals grappling with this challenging condition worldwide.
Which are the best cities for retinitis pigmentosa clinical trials?
When it comes to retinitis pigmentosa clinical trials, several cities are leading the way in research and development. Ann Arbor, Michigan has 8 active trials that investigate treatments such as Genetic: AAV5-RPGR and N-acetylcysteine. Pittsburgh, Pennsylvania also plays a significant role with 7 ongoing studies focused on options like Step 1: SPVN06 dose 1 and Genetic: AAV5-RPGR. Additionally, Gainesville, Florida is actively conducting 7 trials exploring potential breakthroughs including BIIB111 and N-acetylcysteine. These cities offer individuals with retinitis pigmentosa access to cutting-edge clinical trials that bring hope for advancements in care and improved outcomes.
Which are the top treatments for retinitis pigmentosa being explored in clinical trials?
In the realm of retinitis pigmentosa, cutting-edge clinical trials are exploring a range of potential treatments. Notably, N-acetylcysteine has emerged as a promising option, currently being tested in one active trial dedicated to this condition. Another contender is OCU400 High Dose, which also boasts one ongoing trial focused on retinitis pigmentosa. Additionally, researchers are investigating the potential benefits of CNS10-NPC implantation and BS01 through their respective individual trials. As these innovative treatments gain momentum in clinical research since their first listings starting from 2020 onwards, there is hope for improved outcomes for individuals living with retinitis pigmentosa.
What are the most recent clinical trials for retinitis pigmentosa?
Exciting advancements in clinical trials for retinitis pigmentosa offer hope for those affected by this condition. One notable trial is focusing on SPVN06, which has progressed to Phase 2 after showing promising results in Phase 1. Additionally, the OCU400 High Dose trial has reached both Phase 1 and Phase 2 stages, demonstrating its potential as a treatment option. Another study explores Ultevursen's efficacy in treating retinitis pigmentosa, with positive outcomes observed during its progression from Phase 2 to Phase 3. Further research delves into CNS10-NPC implantation as a potential therapeutic intervention at the initial phase of investigation. Finally, MCO-010-High Dose shows promise based on encouraging findings during its advancement through Phase 2 trials. These recent clinical trials offer renewed optimism for individuals living with retinitis pigmentosa and highlight ongoing efforts to find effective treatments for this condition.
What retinitis pigmentosa clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of retinitis pigmentosa, a degenerative eye disease. Notably, Aldeyra Therapeutics successfully concluded a trial for ADX-2191 in July 2022, offering hope for potential therapeutic options. Furthermore, jCyte's investigation into human retinal progenitor cells reached its completion milestone in December 2020. These advancements underscore the ongoing efforts to find effective treatments for retinitis pigmentosa and bring us closer to improving the lives of those affected by this condition.